Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 11/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211606 | 0.94 | LTA4H (0.77) | LTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9122265 | 0.94 | LTA4H (0.77) | LTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5331925 | 0.92 | HRH3 (0.67) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL9097701 | 0.85 | LTA4H (0.66) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL15652139 | 0.85 | LTA4H (0.68) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL5456167 | 0.85 | LTA4H (0.68) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL16825686 | 0.85 | LTA4H (0.68) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL255201 | 0.85 | LTA4H (0.86) | LTA4HHRH3KDM4EALDH1A1BACE1 | |
| SCHEMBL22266156 | 0.84 | LTA4H (0.65) | LTA4HHRH3HRH2HRH1KDM4E | |
| SCHEMBL5752269 | 0.84 | LTA4H (0.64) | LTA4HHRH3HRH2HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | LTA4H 2587/4885HRH3 527/4885HRH2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.